天津医药

天津医药 ›› 2015, Vol. 43 ›› Issue (8): 837-840.doi: 10.11958/j.issn.0253-9896.2015.08.002

• 专题研究·心血管疾病（主编：李广平） • 上一篇    下一篇

LCZ696 开启射血分数减低心力衰竭患者治疗的新时代：来自PARADIGM-HF 的证据

徐延敏，王东昕，崔站前，郭星梅   

  1. 天津医科大学第二医院心内科
  • 收稿日期:2015-07-20 修回日期:2015-07-25 出版日期:2015-08-15 发布日期:2015-08-15
  • 通讯作者: 徐延敏 E-mail:xuyanminphd@aliyun.com

LCZ696 is effective in treating patients with heart failure: based on PARADIGM-HF data

XU Yanmin, WANG Dongxin, CUI Zhanqian, GUO Xingmei   

  1. Department of Cardiology, The Second Hospital, Tianjin Medical University, Tianjin 300211, China
  • Received:2015-07-20 Revised:2015-07-25 Published:2015-08-15 Online:2015-08-15

PDF (PC)

4087

摘要： 心力衰竭（心衰）是由于任何心脏结构或功能异常导致心室充盈或射血能力受损的一组复杂临床综合征，其发病率、病死率高。肾素-血管紧张素-醛固酮系统（RAAS）的长期激活在心衰发生发展的病理生理学机制中发挥着重要作用。血管紧张素转换酶抑制剂（ACEI）、血管紧张素受体拮抗剂（ARB）以及醛固酮受体拮抗剂（MRA）已经被大规模临床试验证实对心衰具有良好的治疗效果，在心衰药物治疗策略中处于重要地位。2014 年8 月30 日在欧洲心脏病学会年会首次公布PARADIM-HF 的研究结果显示，在患者已经使用了β受体阻滞剂和MRA 基础之上， LCZ696 使心血管病死亡风险降低了20%，慢性心衰患者因心衰而住院的次数减少了21%。LCZ696 以其独特的双相作用模式，再次证实调节神经内分泌是治疗心衰的现代观念。LCZ696 将带来传统心衰药物治疗的革新。心衰治疗将大跨步进入一个新时代。

关键词: 心力衰竭, LCZ696, 神经内分泌, PARADIGM-HF

Abstract: Heart failure (HF) is a complex clinical syndrome, which is caused by cardiac structural abnormalities and dysfunction. It can lead to ventricular filling and impaired ejection capacity with high incidence and mortality . The constant activation of the rennin-angiotensin-aldosterone system (RAAS) plays an important role in the development of heart failure. Angiotensin angiotensin converting enzyme inhibitor (ACEI), angiotensin angiotensin receptor antagonist (ARB) and aldoste⁃ rone receptor antagonist (MRA) had been confirmed to be with good therapeutic effects therefore played important roles in heart failure treatment strategy shown by large scale clinical trials. The first PARADIM-HF data published by European So⁃ ciety of Cardiology in annual meeting on August 30, 2014 showed that LCZ696 can reduce cardiovascular mortality risk of HF patient by 20% when combining with beta blockers and MRA . It also reduced the number of hospitalizations of patients with chronic heart failure (CHF) by 21%. LCZ696, using its unique dual phase mode verified that the regulation of neuroen⁃ docrine is the modern concept for the treatment of heart failure. LCZ696 lead to innovation and shed new light in traditional drug treatment for heart failure.

Key words: heart failure, LCZ696, neuroendocrine, PARADIGM-HF